Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies.

Autor:	Akhtar OS; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Szabo A; Division of Biostatistics, Institute of Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Bhatlapenumarthi V; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Forsberg M; Division of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, New York, USA., Balev M; Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA., Patwari A; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Cheruvalath H; Medical College of Wisconsin Medical School, Milwaukee, Wisconsin, USA., Bhutani D; Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA., Thanendrarajan S; Myeloma Center, University of Arkansas for Medical Science, Little Rock, Arkansas, USA., Dhakal B; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Zangari M; Myeloma Center, University of Arkansas for Medical Science, Little Rock, Arkansas, USA., Patel T; Myeloma Center, University of Arkansas for Medical Science, Little Rock, Arkansas, USA., Shrestha A; Myeloma Center, University of Arkansas for Medical Science, Little Rock, Arkansas, USA., Al-Hadidi S; Myeloma Center, University of Arkansas for Medical Science, Little Rock, Arkansas, USA., Cooper D; Division of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, New York, USA., Lentzsch S; Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA., van Rhee F; Myeloma Center, University of Arkansas for Medical Science, Little Rock, Arkansas, USA., Shah MR; Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA., Bag A; Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA., D'Souza A; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Schinke C; Myeloma Center, University of Arkansas for Medical Science, Little Rock, Arkansas, USA., Chakraborty R; Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA., Shah N; Division of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, New York, USA., Mohan M; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Jazyk:	angličtina
Zdroj:	British journal of haematology [Br J Haematol] 2024 Aug 27. Date of Electronic Publication: 2024 Aug 27.
DOI:	10.1111/bjh.19700
Abstrakt:	The Glasgow prognostic score (GPS) and CAR-HEMATOTOX (CAR-HT) score identify multiple myeloma (MM) patients at high risk for immune-mediated toxicity and early mortality with cellular immunotherapy. However, their association with outcomes in patients receiving T-cell redirecting bispecific antibodies (bsAb) is unclear. This multi-centre retrospective study examines the association of baseline GPS and CAR-HT scores with outcomes in 126 MM patients treated with bsAb. Overall, 19% were identified as GPS high risk but did not experience increased toxicity or mortality. Conversely, high-risk CAR-HT patients had a higher incidence of infections and inferior survival, suggesting a need for aggressive infection mitigation strategies. (© 2024 British Society for Haematology and John Wiley & Sons Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text